Suggestions
Nina Dudnik, PhD
Innovation, entrepreneurship, and ecosystem building || Board Director, speaker, super-connector
Nina Dudnik, PhD, is a prominent figure in the fields of innovation, entrepreneurship, and ecosystem building. She currently serves as a Senior Commercialization Advisor at NobleReach Foundation, leveraging her extensive experience in the life sciences and startup sectors.14
Dr. Dudnik possesses significant technical knowledge and research experience, which she applies to her work in venture investment and workforce development, particularly in the Chicago area.12 Her expertise spans various domains, including synthetic biology, biological herbicides, and life science startups.356
Throughout her career, Nina has been actively involved in:
- Supporting life science startups, offering guidance as an independent board member and advisor.6
- Attending and analyzing industry events, such as SynBioBeta, to stay current with developments in synthetic biology.3
- Promoting innovative projects, like The Toothpick Project, which focuses on biological herbicides.5
- Collaborating with organizations like the National Science Foundation (NSF) to select and support innovative projects.8
Dr. Dudnik's LinkedIn profile showcases her commitment to fostering innovation and supporting entrepreneurship in the life sciences sector. Her posts and activities demonstrate a keen interest in emerging technologies and their potential applications in solving real-world problems.27
Highlights
📣 It's time to #vote! 🗳
No, not in that election, not yet anyway.
I need your vote for our terrific panel suggestion for next year's South by Southwest #SXSW.
Go here to vote by August 18: https://lnkd.in/grVfDbn4
Your vote can send this #AllWOMENpanel (and all #Chicago!) - Nina Dudnik,(that's me), Lisa Dhar, Dimitra Georganopoulou, and Julie Ming Liang - to #SXSW in March to talk about the challenges - pro and con - of taking basic science out of the lab and turning it into #ventures and impact.
Thank you for supporting us!
Feeling thoroughly biologized! What a thrill to go to SynBioBeta this week. It's been exactly 5 years since the last time I attended, and it was fascinating to see how much had changed, and the core themes that kept recurring:
-
5 years ago, enzymatic DNA synthesis was still an aspiration. Now it's a reality. I'm a dinosaur who hand-sequenced DNA once upon a time, so the ability to order DNA on demand from so many different companies made through so many different processes is how I know I'm living in the future.
-
There hadn't been serious commercial products from synbio 5 years ago, and I remember fielding accusations that maybe it was all fiction. Now we can point to alt-meats, food ingredients, and some materials that have gone mainstream, not to mention a few huge acquisitions that have given real proof to the ambitions.
-
I've rolled my eyes more than once at the buzzy use of AI. But I was drawn in by the new models being developed to understand genomes, predict protein folding, and hopefully design new enzymes with never-before-seen functions in the near future.
-
It was nice to see the collaboration between industry and government around issues of biosafety and regulation, getting out ahead of the issues instead of waiting for a crisis.
-
I may never recover emotionally from the failures in the late '90s to introduce GMO's to the public. There's a huge investment in alternative proteins and other ingredients as a means to mitigate the climate impacts of our food chain -- and we're going to need to do better on both public education and marketing to make sure they succeed. (I'm a little disappointed I didn't get to eat any bioengineered ice cream.)
Loved seeing so many old and new friends. Christina Agapakis, Michael Baffi, PhD, Ben Kellogg, Melina Fan, Will Kools, Michael Hallstrom, Florence Chaverneff, Sarah R. Carter, Ph.D., Yolanda F., Joseph Buccina, and the growing Chicago contingent: Katherine "Kit" McDonnell, Michael Köpke, Gerry Sapienza, Julie Ming Liang, Khalid K. Alam, Ph.D.
All in all, #synbio really convenes the bio-optimists, and I'm feeling hopeful about what this community is going to build next.
